As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in areas to drive future grow. These include access to novel molecules, consumer health and digital health solutions.
Access to Novel Molecules
We are collaborating with multiple innovator companies to bring their innovative products to India and other emerging markets which will increase access of these products. We are investing in building capabilities for CAR-T in India with support of our licensing partners. Our wholly-owned subsidiary, Aurigene Oncology Limited (AOL), is engaged in discovery and early clinical development of novel, best-in-class therapies to treat cancer and inflammatory diseases.
Consumer Health
We are expanding our consumer health portfolio to serve a greater number of patients directly. While Russia, certain CIS countries and India already have an established consumer health business, we are now strengthening our presence in markets such as US and the UK. Additionally, we are establishing our presence in the direct business channel through e-commerce for select markets.
Digital Health Solutions
Digital healthcare spans a wide spectrum of solutions, including digital therapeutic products offering drug-free treatment and disease management platforms that enable patients to better manage their condition. In FY’24, we launched a digital therapeutics product Nerivio®, for migraine management and a digital platform DailyBloom™, for IBS condition management. We believe this is an evolving space that will help to address unmet patient needs in the coming years.
